Welcome to our dedicated page for Dianthus Therapeutics SEC filings (Ticker: DNTH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Dianthus Therapeutics filings document the regulatory record of a clinical-stage biotechnology company developing therapies for severe autoimmune diseases. The company’s 8-K reports furnish operating and financial results, corporate presentations, clinical-program disclosures for claseprubart, FDA feedback on trial screening and safety-risk language, and updates tied to programs in neuromuscular and rheumatology indications.
Other filings cover capital-structure and governance matters, including common stock listed on the Nasdaq Capital Market, underwritten public offering agreements, pre-funded warrant terms, shareholder voting matters, proxy disclosure, material agreements, and equity-compensation actions. These records also describe risk-factor and forward-looking disclosure around clinical development, regulatory interactions, financing needs and public-company governance.
Dianthus Therapeutics director Simon Read reported a grant of 6,090 stock options. These options give him the right to buy 6,090 shares of common stock at an exercise price of 89.63 per share and expire on May 21, 2036.
The award will vest in full on the earlier of the first anniversary of the May 21, 2026 grant date or the company’s 2027 annual stockholders’ meeting, as long as he continues serving the company through that vesting date. This is a compensation-related grant, not an open‑market purchase or sale.
Dianthus Therapeutics director Steven J. Romano received a grant of stock options covering 6,090 shares of common stock. The options have an exercise price of $89.63 per share and expire on May 21, 2036. According to the terms, all 6,090 underlying shares will vest in full on the earlier of the first anniversary of the May 21, 2026 grant date or the company’s 2027 annual meeting of stockholders, provided he continues serving the company through that vesting date.
Dianthus Therapeutics director Alison Frances Lawton received a grant of stock options covering 6,090 shares of common stock. The options have an exercise price of $89.63 per share and expire on May 21, 2036. Following this award, she holds 6,090 stock options directly.
According to the grant terms, all shares underlying this option will vest in full on the earlier of the first anniversary of the grant date or the company’s 2027 annual meeting of stockholders, as long as she continues to serve the company through the vesting date.
Dianthus Therapeutics director Anne McGeorge received a grant of stock options, not a market purchase or sale. The award covers 6,090 options to buy common stock at an exercise price of $89.63 per share, expiring on May 21, 2036.
According to the terms, all 6,090 underlying shares will vest in full on the earlier of the first anniversary of the grant date or the company’s 2027 Annual Meeting of Stockholders, as long as she continues serving the company through that vesting date.
Dianthus Therapeutics director Sujay Kango received a grant of stock options covering 6,090 shares of common stock. The options have an exercise price of $89.63 per share and expire on May 21, 2036. Following this award, Kango holds 6,090 derivative securities in the form of these options.
According to the vesting terms, all 6,090 underlying shares will vest in full on the earlier of the first anniversary of the grant date or the company’s 2027 Annual Meeting of Stockholders, provided Kango continues to serve the company through that vesting date.
Dianthus Therapeutics director Jonathan Violin received a compensation-related stock option grant. He was awarded options to purchase 6,090 shares of common stock at an exercise price of $89.63 per share, expiring on May 21, 2036.
The options will vest in full on the earlier of the first anniversary of the grant date or the company’s 2027 Annual Meeting of Stockholders, provided he continues to serve the company through that date. After this grant, he holds 6,090 stock options directly, with no open-market share purchases or sales reported in this filing.
Dianthus Therapeutics director Paula Soteropoulos received a grant of stock options covering 6,090 shares of common stock. These options have an exercise price of $89.63 per share and expire on May 21, 2036. Following this award, she holds 6,090 derivative securities linked to common stock.
The underlying 6,090 shares of common stock will vest in full on the earlier of the first anniversary of the grant date or the company’s 2027 Annual Meeting of Stockholders, provided she continues serving the company through the vesting date. This is a compensation-related award rather than an open-market purchase or sale.
Dianthus Therapeutics reported results from its annual stockholder meeting held on May 21, 2026. Stockholders elected Sujay Kango, Anne McGeorge and Jonathan Violin, Ph.D. as Class II directors to serve until the 2029 annual meeting. An advisory vote approved executive compensation, with 41,004,507 votes for and 1,713,043 against. Stockholders also ratified Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 46,298,319 votes for and minimal opposition.
Dianthus Therapeutics ownership update: RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., Peter Kolchinsky and Rajeev Shah report beneficial ownership of 2,611,733 shares of Common Stock, equal to 4.8%, reported as of March 31, 2026.
The filing states the Fund directly holds 2,611,733 shares, that the percentage is calculated using 54,448,771 shares outstanding as of March 30, 2026, and that RA Capital has been delegated voting and dispositive power over the Fund's holdings. The Reporting Persons disclaim group status and disclaim beneficial ownership for purposes described in the text.
Dianthus Therapeutics filed Amendment No. 2 to a Schedule 13G/A reporting beneficial ownership of 643,599 shares of Common Stock, representing 1.2% of the class as of the close of business on March 31, 2026.
The filing identifies Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen as the reporting persons; the shares are held through an investment fund managed by Point72 and are reported as shared voting and dispositive power. The percentage basis is an aggregate of 52,942,083 Shares outstanding derived from offering and prior outstanding counts disclosed in the filing.